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ABSTRACT
An anthropometric and therefore cost-neutral screening approach as an indi-
cator of the abuse of anabolic steroids by bodybuilders is the fat-free mass 
index (FFMI). Normalized to a body size of 1.80 m, the FFMI is  calculated 
as follows: FFMI = lean mass (in kg) / body height (in m)² + 6.1 × (1.8 – 
body height (in m)). Furthermore, various physical and anthropological 
symptoms can be summarized as evidence of anabolic steroids or growth 
hormone abuse as doping signs or doping stigmata. Doping stigmata are 
 usually identifiable doping signs in the external appearance. Typical doping 
signs for anabolic steroids are testicular atrophy, swollen, voluminous mus-
cles with elusive smooth contours, exophthalmus, alopecia androgenetica, 
steroid acne, gynecomastia, cutis verticis gyrata, striae distensae, seborrhea, 
hematomas, an unproportional development of the upper body compared 
to the rest of the body and, in females, hirsutism, hypertrichosis, mam-
mary atrophy and masculine growth in width, extreme reduction of subcu-
taneous fat percentage, lowering of the voice, clitoris hypertrophy, secondary 
 amenorrhoea and  the irreversible androgenization of a female fetus during 
pregnancy. Doping stigmata for growth hormone are gigantism, acromegaly, 
macroglossia, tooth gaps, prognathism,  torus supraorbitalis, visceromegaly 
(cardiomyopathy, splenomegaly and hepatomegaly), hairs of wire brush con-
sistency, edema, seborrhoea, skin thickening and hypertrichosis, cutis verticis 
gyrata and the reduction of the percentage of fat. Typical examples of dop-
ing signs of  erythropoietin are plethora and rubeosis faciei. Doping stigmata 
of  amphetamines are, for example, tachycardia, hypertension, decongestion, 
tremor, mydriasis or speed pimples.
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INTRODUCTION
Body builder disorders such as inverse anorexia (synonyms: bigorexia nervosa, 
machismo nervosa, muscle dysmorphia) may play a role as additional doping 
motives, especially for recreational bodybuilders [45], primarily in the case of 
deficient muscle expression.
While anorectic patients often experience too much fat despite malnutri-
tion, the inverse anorectics feel too thin and unmasculine despite Mr-Universe-
like body shape (Fig.1).
Figure 1. Cartoon: anorexia nervosa (left) vs. inverse anorexia (right)
DOPING EPIDEMIOLOGY IN GERMAN FITNESS STUDIOS
In a survey of 484 recreational athletes in 11 gyms in the area of Frankfurt/
Main, 12.9% of the men and 3.6% of the women reported taking anabolic drugs. 
They consumed anabolic steroids (100%; 35% p.o., 71% parenterally), stimu-
lants (14%) and growth hormones (5%). Suppliers were friends (39%), sports 
mates (28%), physicians (28%) and coaches (6%). The acquisition costs of an 
average intake for 9 weeks amounted to 175 euros. Information about doping 
side effects came from literature (67%), physicians (38%), sports mates and the 
so-called Black Book [72] (14% respectively), coaches, friends and Internet (5% 
respectively). 2% of the athletes with doping substances abuse were smokers, 
11% had an alcoholic drink several times a week, 3% also consumed other 
drugs, 35% had consumed other drugs in the past. Abusers of doping sub-
stances primarily intended to increase muscle size (86%) and strength (61%).
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A POTENTIAL SCREENING METHOD IN BODYBUILDING?
Kouri et al. [31] introduced an anthropometric and, therefore, cost-neutral 
screening approach as an indicator of anabolic steroids abuse by bodybuilders: 
the fat-free mass index (FFMI), which could also be called the lean body mass 
index.
Dimensionally, it is designed analogously to the well-known body mass 
index (BMI), which sets the body mass in relation to the squared body height.
For the FFMI, the percentage of fat according to Jackson and Pollock [24] 
must first be determined using six skinfolds in mm (breast, thigh, suprailiacal, 
abdominal, subscapular and triceps skinfolds) and then, taking into account 
the body weight, the lean mass can be calculated.
Normalized to a body height of 1.80 m, the FFMI is calculated as follows:
FFMI = lean mass (in kg) / body height (in m)² + 6.1 × (1.8 – body height 
(in m))
Based on an investigation on the FFMI in a collective of 157 male body-
builders (83 users of anabolic steroids and 74 non-users), Kouri et al. [31] 
found that the pathological limit of the FFMI was 25.0. So-called natural body-
builders, who oppose the use of anabolic steroids, were all below the 25.0 level, 
while many of the anabolic steroids users were above. Remarkably, the aver-
age value of Mr. America bodybuilding competitors of the pre-anabolic area 
(1930–1950) was 25.4.
SIDE EFFECT PROFILES AND DOPING STIGMATA OF SELECTED 
DOPING SUBSTANCES
The present publication focusses on the anabolic steroids and the growth hor-
mone [70], which are the most important substances in the field of weight train-
ing, erythropoietin and blood doping [42], which are important for endurance 
sports, as well as amphetamine and cocaine from the stimulant group [29, 30].
Anabolic steroids 
The effect of the anabolic steroids and androgens used in sports since the 1950s 
is attributed, on the one hand, to the direct increase in protein biosynthesis [70] 
and, on the other hand, to a more aggressive behaviour in strength training.
Pharmacologically, the synthetic anabolic steroids are similar to testoster-
one or 19-nortestosterone. Since testosterone is rapidly metabolized and thus 
 inactivated in the liver, incorporation of alkyl groups at position C17 of the 
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steroid molecule (Figure 2) can modify its molecular structure with the conse-
quence of a significantly slower enzymatic degradation in the liver. Therefore, 
synthetic anabolic steroids could also be applied orally. Unfortunately, these 
C17-alkylated androgens are not negligible in liver toxicity.
Figure 2. Basic formula of anabolic steroids
Steroid doping stigmata in males
Doping stigmata (Figure 6) are usually identifiable doping signs in the external 
appearance [33, 52, 54, 59].
As a result of the negative feedback inhibition, a downregulation of the hor-
mones can take place, formed in the anterior lobe of the pituitary gland [83], 
which stimulates or controls the function of the male gonads, the so-called 
gonadotropins.
A consequence may be a large reduction in sperm in the ejaculate or the 
complete absence of seminal maturation cells and sperm cells in the ejaculate 
(azoospermia) with infertility.
In shrinking testes (= testicular atrophy), the testes are correspondingly 
greatly reduced.
The term “swelling muscles” [33] denotes swollen, voluminous muscles 
with elusive smooth contours. This is a consequence of water retention as a 
dreaded side effect of anabolic steroids, especially in competitive bodybuilders, 
which jeopardizes competitive success.
Exophthalmos (also called exophthalmus, exophthalmia, proptosis, or exor-
bitism) is a bulging of the eye anteriorly out of the orbit. It is a symptom of 
Graves’ disease, which is also known as toxic diffuse goiter, an autoimmune 
disease that affects the thyroid. With anabolic abuse, the exophthalmos is the 
result of local water retention.
The causes for balding of the male type (alopecia androgenetica) are heredi-
tary conditions, a corresponding high androgen level and age. The hair loss 
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begins at the so-called receding hairline [3]. Anabolic steroids accelerate the 
mentioned process.
In the case of steroid acne (Fig. 3a+b), androgens stimulate sebum secretion 
at different ages in all age groups [3].
Figure 3a+b. Pronounced steroid acne (course) in a bodybuilder
Gynecomastia (Fig. 4) is the enlargement of the mammary gland [75], which, 
in principle, can occur with the supply of testosterone or anabolic steroids in 
every healthy male athlete. According to O’Sullivan et al. [43], its prevalence is 
at 20–30%. This feminizing side effect of anabolic steroids is said to be caused 
by a compensatory increase in the production of female hormones (oestrogens) 
as a result of the increased intake of male hormones [33].
Figure 4. Initial gynecomastia in a competitive bodybuilder
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On the other hand, testosterone can also be partly converted into oestrogen 
in the fat and muscle tissue by means of the enzyme aromatase, so that gyne-
comastia can also be a direct consequence after administration of testo sterone 
esters. Due to the possibility of the transformation of anabolic steroids into 
oestro gens by aromatization in the periphery, not only gynecomastia with 
potential chest pain is threatening in male athletes but according to some 
authors [58], also higher vocal tracts.
Often there is a need for surgical removal of the mammary gland (mastec-
tomy) with areola and nipple preserved [75].
Cutis verticis gyrata, (Fig. 5a+b) is a fold-like thickening of the scalp which, 
in the clinical picture, shows a clear similarity to the folds (gyri) of the brain 
surface [54]. 
Hair growth in the furrows is usually normal but diminished on the skin 
folds. One risk factor is the rapid increase in muscle mass under anabolic 
 steroids.
Figure 5a+b. Cutis verticis gyrata
Stretch marks (striae distensae) develop in the hypodermis (subcutis) as a 
result of excessive tissue expansion, especially in the area of the upper body 
and upper arm due to muscle growth that is much too rapid [3].
Seborrhea is a pathologically increased secretion of the sweat glands under 
anabolic steroids.
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Other signs of doping include the increased occurrence of bruising (hema-
tomas), an disproportionate development of the upper body compared to 
the rest of the body, the increased risk of tendon and muscle injuries [88], 
 accelerated maturation in adolescents and punctures of larger muscle groups 
as an indication of parenteral use.
Doping stigmata in females
Without medication, women in certain strength sports accomplish only 60% 
of male performance [48].
Sportswomen who use androgens and anabolic steroids are also  threatened 
by the doping stigmata (Fig. 6) described in the previous section for male 
 athletes: swelling muscles, exophthalmos, alopecia androgenetica and steroid 
acne, as well as increased aggressiveness (Fig.3). In addition, the following 
 doping stigmata may occur:
Hirsutism (a male distribution pattern of terminal hair in females; [3]); 
hypertrichosis and mammary atrophy (loss of mammary tissue).
The most striking feature is a masculine growth in width [33].
In addition to muscle development, the extreme reduction of subcutane-
ous fatty tissue is particularly impressive. After discontinuation of the hor-
mones, the hormone-induced muscles decrease again, and the percentage of 
fat increases in a gender-appropriate manner.
In addition, an increase in size (hypertrophy) of the thyroid cartilage and 
lowering of the voice can occur, analogously to the developments in pubescent 
boys. Clitoral enlargement (clitoris hypertrophy, clitoromegaly or megalocli-
toris) can be induced by anabolic steroids.
As in the male sex, the libido in the athlete under anabolic steroids / andro-
gens is often massively increased. The absence of menstruation under andro-
gens / anabolic steroids is a secondary amenorrhoea.
One of the worst side effects is certainly the irreversible androgenization 
of the female foetus during pregnancy. The inner genitals, on the other hand, 
are female.
If the growth in heighth has not yet been completed, a premature epiphyseal 
closure can happen in both sexes [51].
Liver damage caused by anabolic steroids or androgens
Similarly to the observations under oral contraceptives, GOT, GPT and LDH 
can exceed the norm by 2–3 times. According to some authors [54] GOT, GPT 
and γ-GT reach their peak within 14 to 21 days under anabolic steroids – even 
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at low dosage – and return to normal range already a few weeks after discon-
tinuation of doping.
According to some studies, jaundice occurs up to more than 17% frequently 
with anabolic steroids. Gallstones can also occur frequently.
Peliosis hepatis is an uncommon vascular condition characterized by 
 multiple, randomly distributed, blood-filled cavities throughout the liver. The 
size of the cavities usually ranges between a few millimetres and 3 cm in dia-
meter. It is often the result of the use of C17-alkylated androgens. In isolated 
cases, deaths due to internal bleeding and liver failure may also be present in 
this disease. Many patients can also be quite symptom-free. The diagnosis is 
then often made only at autopsy [68, 32].
In addition, individual case descriptions of liver tumours such as adenomas 
(benign tumours of the glandular tissue or mucosa) due to anabolic steroids 
are documented in scientific literature, often occurring after discontinuation 
of the anabolic steroids. However, Sweeney and Evans [77] suspect that, under 
the steady influence of anabolic steroids, simple liver changes, such as liver fatty 
degeneration, may initially develop. Later follow-up would be Peliosis hepatis, 
later also liver adenomas and, in the worst case, even the development of liver 
cancer.
Cardiovascular diseases caused by anabolic steroids and androgens
Anabolic-androgenic steroids can [17] directly or indirectly cause cardiac 
arrhythmias as a consequence of direct myocardial cell damage and/or electro-
physiological changes.
An unfavourable change in the lipoprotein concentration in the blood can 
induce premature arteriosclerosis. Arterial hypertension, increased risk of 
thrombosis or vasospasm are also possible [69].
The long-term use of anabolic steroids can also trigger so-called left 
 ventricular hypertrophy (LVH) [11, 12, 13, 86, 64, 65, 38, 47, 10, 27, 26, 9, 81, 
7, 20, 41, 34, 79, 78, 28].
Other long-term consequences
There are individual case descriptions [39, 57] of the development of lesser 
kidney damage to acute renal failure, but also on the inflammation of the filter 
cells in the renal corpuscles (glomerulonephritis) and even a malignant kidney 
tumour (Wilms tumour) under long-term effect of anabolic steroids.
There are also reports of dialysis after steroid and clenbuterol abuse over 
18 months [19], of prostate cancer [63] and testicular cancer [16] as well as 
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malignant diseases of the lymphatic system (non-Hodgkin’s lymphoma) under 
anabolic steroids [80].
Dental studies also indicate an association between the use of anabolic 
 steroids and the development of gingival hyperplasia [44].
Damage to the musculoskeletal system
From a probable total group of 1000 GDR athletes badly damaged by doping, 
Spitzer investigated a stratified sample of 52 persons from 24 disciplines on the 
Olympic level (canoe racing, rowing, athletics etc.) and interviewed them from 
2004 to 2006 [73, 74]. 92% of respondents complained of numerous musculo-
skeletal disorders.
A high degree of compatibility with Spitzer’s publications can be found 
in an extensive study of 2552 former American professional football players 
from 2009. Horn, Gregory and Guskiewicz [23] from the University of North 
 Carolina investigated the relationship between anabolic steroids consumption 
and musculoskeletal disorders. 9.1% of respondents had used anabolic steroids 
during their professional career. In this study, a very significant (p < 0.005) cor-
relation was found between herniated discs and the use of anabolic  steroids. 
Back pain was reported by 73.4% of anabolic steroid users compared with 
54.5% of non-users. This relationship was also very significant (p < 0.005).
Growth hormone
If the hormone were administered to children or adolescents in certain sports 
(basketball, football, volleyball), even if it is a horror concept, a giant growth 
(gigantism) could be induced.
The typical doping stigmata [52] under STH influence after completion 
of growth (Fig. 6) include acromegaly, a large, chubby hand, macroglossia, 
enlarged interdental spaces (tooth gaps), prognathism and supraorbital or 
supraorbital bulging (Torus supraorbitalis) [54].
Other signs are a disturbance of glucose tolerance, diabetes mellitus [67], 
myopathy [14], visceromegaly [54], divided into individual symptoms of cardio-
myopathy, splenomegaly and hepatomegaly [69]. Characteristic of the effects 
of STH are also hairs of wire brush consistency, oedema and skin reactions at 
the site of injection [3], hirsutism, lipodystrophy and exfoliative dermatitis.
Schaffert and von Werder [67] describe the frequently complained sweat 
tendency, seborrhoea, skin thickening and hypertrichosis. Sinner [72]  attributes 
nocturnal sweats and sleep disturbances to evening growth hormone injections 
in doping athletes. Further skin manifestations are, according to Schaffert and 
von Werder [67], thickened veins and nails, facial swelling, scalp thickening 
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(Cutis verticis gyrata) already described in the chapter on anabolic steroids, 
and a carpet-like black pigmentation of the skin (acanthosis nigricans).
A desirable effect of GH is the reduction of the percentage of fat. However, 
an increase in the concentration of free fatty acids in the plasma can also be 
registered. Under STH influence, however, there is also an unfavourable ratio 
of blood lipids (dyslipidaemia) [69].
One of the consequences of cranial bone changes with the radiologically 
detectable thickening of the inner layer of the skull bone (tabula interna) and a 
significant enlargement of the frontal sinus is headache [67].
According to Kamber and Mullis [25], one symptom of intracellular water 
retention under STH is the so-called carpal tunnel syndrome, in addition to 
ankle oedema and joint pain (arthralgia). Thyroid dysfunction is the result of 
general visceromegaly.
The excessive cartilage growth under GH also leads to a nonphysiological 
enlargement of the joint space, so that first a cartilage nutritional disorder and 
then a cartilage degeneration which results in arthropathy (joint disease) [67]. 
Correlations between growth hormone intake and colon carcinoma, breast 
cancer as well as prostate cancer and leukaemia are discussed. Magnavita and 
coworkers [36] reported a case study on a cyclist who received growth hor-
mone and developed Hodgkin’s lymphoma (a form of malignant lymphoma). 
The increased development of benign skin tumours (fibroids) and colonic 
 polyps is also typical [67].
Erythropoietin and blood doping
Erythropoietin (EPO) induces an increase of red blood cells (erythrocytes) in 
the blood with an increase of the erythrocyte mass and haemoglobin. As a con-
secutive doping sign (Fig.6), plethora and rubeosis faciei could be observed.
The hyperviscosity syndrome is a complex of symptoms that results from 
increased viscosity of blood.
According to Nowacki [42], the haematocrit values of certain cyclists dur-
ing some races even exceeded 60%. Typical symptoms of this hyperviscosity 
syndrome include headache, dizziness, tinnitus, hearing and vision disorders, 
paraesthesia, angina pectoris and syncope (fainting). According to Nowacki 
[42], there is an increased risk of thrombosis, hypertension, heart failure and 
pulmonary oedema.
Lunghetti et al. [35] reported a complicated myocardial infarction of a 
50-year-old bodybuilder with consecutive cardiogenic shock after taking 
 nandrolone and erythropoietin. Allergic reactions, haemolysis, jaundice and 
sepsis may happen.
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Stimulants
According to Clasing [6], stimulants are considered the “classic” doping agents 
which are supposed to postpone the fatigue limit directly during the competi-
tion. They may cause danger to life, above all, under the influence of additional 
stress factors such as heat exposure, fluid loss or trauma etc. [50, 82, 4, 8].
Koch [29] characterizes the psychophysiological effect as an escape response 
in acute danger. This range of effects also corresponds to some side effects such 
as restlessness, disinhibition, reduction in criticism, euphoria, nervousness, 
sleep disorders, daytime sleepiness and also turning into severe fatigue.
Even delirious symptoms with attention and consciousness disturbances 
or perceptual changes, delusions, visual and auditory hallucinations can occur 
[30].
Likewise, panic, depression, paranoia or fear of death can occur [30].
According to Forth et al. [15], amphetamine acts as an appetite inhibitor.
Acute side effects of taking amphetamines [29] are tachycardia (accelerated 
pulse of over 100 beats per minute), hypertension, decongestion (decongest-
ant effect in the area of the nasal mucosa), hyperthermia, tremor, mydriasis, 
hypoglycaemia, bronchodilation, increased muscle tears, dehydration, rhabdo-
myolysis, seizures, coma, stomach bleeding, brain and heart attacks, sexual dys-
function, kidney damage, speed pimples and the serotonin syndrome (Fig.6).
Cocaine
According to Koch [30], the acute effect of cocaine is characterized by a “kick” 
with euphoria and happiness, subjectively increased performance, increased 
libido, reduction of inhibition, decrease in hunger and thirst as well as depres-
sion and anxiety. According to Koch [30], the euphoria is often followed by 
depressive mood.
Somatic symptoms include tachypnoea, Cheyne-Stokes respiration, tachy-
cardia, hypertension, mydriasis, dehydration or a nasal septum damage (Fig.6).
It is also difficult to foresee potential, severe cardiac arrhythmias such 
as ventricular fibrillation. Logorrhoea denotes an obviously uncontrollable, 
hardly interruptible speech as a result of lack of self-control. As an intoxication, 
epileptic seizures can occur. The term hyperthermia indicates a pathological 
overheating of the body.
According to Koch [30], chronic side effects include brain and heart attacks, 
sexual dysfunction, weight loss, liver damage, severe mental dependency, para-
noid hallucinatory syndromes (e.g., cocaine beetles), panic attacks or delirious 
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syndromes, dysphoria, aggression, depressed-impulsive syndromes, prolonged 
withdrawal syndromes, embryo- and fetotoxicity.
As typical withdrawal symptoms, Koch [30] lists strong cravings, depres-
sion, anxiety, loss of drive, fatigue as well as accompanying vegetative symp-
toms such as sleep disturbances, sweating, vomiting and diarrhoea.
Figure 6. Synopsis of typical doping stigmata: testosterone / anabolic steroids in man and 
woman, growth hormone, cocaine, stimulants, EPO and blood doping
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